zileuton
information and resources from the National Cancer Institute
NCI Thesaurus | zileuton
A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. NCI Thesaurus | zileuton
A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma.
|
|
|
|
news articles
Critical Therapeutics Announces Research on ZYFLO(R) Presented at ... Mar 6, 2006
Genetic Engineering News, Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that two scientific posters on ZYFLO(R) (zileuton tablets) were presented at the American Academy of ...
Critical Therapeutics Announces Research on ZYFLO Presented at ... Mar 6, 2006
PharmaLive.com (press release), ...(Nasdaq: CRTX) today announced that two scientific posters on ZYFLO(R) (zileuton tablets) were presented at the American Academy of Allergy, Asthma & ...
Mc|K Advertising chosen to promote ZYFLO from Critical ... Mar 13, 2006
PharmaLive.com (press release), Critical Therapeutics, Inc. of Lexington, MA for the professional marketing and promotion of ZYFLO® (zileuton tablets). ZYFLO was ...
Critical Therapeutics Announces Decision to Discontinue Clinical ... Mar 15, 2006
Genetic Engineering News, ...diseases. The Company owns worldwide rights to the asthma drug ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ...
State could lose its food safety labels Mar 6, 2006
Sacramento Bee, ...cause cancer or birth defects. Some 750 chemicals are now listed, from acetaldehyde to zileuton. California and other states impose ...
Critical Therapeutics Initiates Pharmacokinetic Studies of ... 21 Dec 2005
PharmaLive.com (press release), ...(Nasdaq: CRTX) today announced that it has initiated two definitive pharmacokinetic studies comparing the bioavailability of zileuton controlled-release (CR ...
Research In Motion, Micron, Tibco, Bed Bath & Beyond 21 Dec 2005
Investor's Business Daily (subscription) ...(CRTX) said it has initiated two new pharmacokinetic studies of zileuton to support a new drug application for a twice-a-day formulation. ...
Critical Therapeutics to Initiate Clinical Study of Intravenous ... Dec 19, 2005
Genetic Engineering News, ...announced that the 30-day waiting period relating to the Company's Investigational New Drug application for the intravenous formulation of zileuton (zileuton IV ...
Critical Therapeutics Achieves Collaboration Milestone in HMGB1 ... Dec 8, 2005
Genetic Engineering News, ...care diseases. The Company owns worldwide rights to ZYFLO(R) (zileuton tablets), as well as other formulations of zileuton. ZYFLO ...
|
|
